Search

CN-122005585-A - Application of saponin compound in preparation of medicine for treating rheumatoid arthritis

CN122005585ACN 122005585 ACN122005585 ACN 122005585ACN-122005585-A

Abstract

The invention provides application of a saponin compound in preparing a medicine for treating rheumatoid arthritis. The saponins have a structure shown in formula (I). Wherein X and R1-R7 are as defined in the specification. A series of animal experiments prove that the saponin compound provided by the invention has the capability of obviously relieving the symptoms of the rheumatoid arthritis and reducing the related serum inflammation indexes, and can be used as a potential rheumatoid arthritis treatment drug.

Inventors

  • XIA ZENGHUA

Assignees

  • 苏州禾研生物技术有限公司

Dates

Publication Date
20260512
Application Date
20241111

Claims (8)

  1. 1. The application of a saponin compound shown in a formula (I) and pharmaceutically acceptable salts, esters, prodrugs or solvates thereof in preparing medicaments for treating rheumatoid arthritis is disclosed, wherein, the= represents a double bond or a single bond, Represents a single bond or no bond, two adjacent ones of which are not simultaneously double bonds, when When a single bond is formed, the carbon attached thereto is a single bond, when When there is no bond, the carbon attached thereto is either a double bond or a single bond, and R1 and R3 are selected from H, OH, CH 3 , and , , Any one or two or three of the glycosyl residues formed by condensation, R2, R4-R7 are independently selected from H, OH, CH 3 ,CHO,OCH 3 。
  2. 2. The use according to claim 1, wherein the saponins compound has a structure shown in formula (II), wherein R11 and R12 are selected from H, OH, CH 3 , and , , Any one or two or three of the glycosyl residues formed by condensation, R13 is selected from H, CH 3 or CHO, R14-17 is selected from H, OH, CH 3 ,OCH 3 。
  3. 3. The use according to claim 1, wherein the saponins compound has a structure shown in formula (III), wherein R21 is selected from H, OH, CH 3 , and , , Any one or two or three of the glycosyl residues formed by condensation, R22 is selected from H and OCH 3 。
  4. 4. The use according to claim 1 or 2, wherein the saponins have the structure shown below:
  5. 5. the method according to claim 1 or 3, wherein the saponin compound has the structure shown as follows:
  6. 6. the use according to any one of claims 1 to 5, wherein the medicament further comprises a pharmaceutically acceptable carrier.
  7. 7. The use according to any one of claims 1 to 6, wherein the medicament is formulated into clinically acceptable tablets, capsules, oral liquids, powders, drop pills, granules or injections by adding conventional excipients.
  8. 8. A pharmaceutical composition for the treatment of rheumatoid arthritis, comprising a saponin compound according to any one of claims 1 to 5 and pharmaceutically acceptable salts thereof.

Description

Application of saponin compound in preparation of medicine for treating rheumatoid arthritis Technical Field The invention belongs to the field of medicines, and in particular relates to application of a saponin compound and pharmaceutically acceptable salts thereof in preparation of a medicine for treating rheumatoid arthritis, and a medicine composition for treating rheumatoid arthritis. Background Rheumatoid Arthritis (RA) is a chronic, systemic disease with an unknown etiology, mainly inflammatory synovitis, and is characterized by polyarthritis, symmetry, and invasive joint inflammation, wherein rheumatoid arthritis mainly affects small joints such as hands and feet, and is generally distributed symmetrically, and inflammation is invasive and gradually damages joint structures. In addition to joint inflammation, rheumatoid arthritis may also affect other organs and systems, such as the heart, lungs, kidneys, etc. The elevated level of rheumatoid factors in the blood of most rheumatoid arthritis patients is one of the important indicators for diagnosing the disease. The synovial tissue of rheumatoid arthritis patients undergoes proliferative changes, resulting in thickening of the synovium. Interstitial mass inflammatory cell infiltration, i.e. infiltration of a large number of inflammatory cells (such as lymphocytes, macrophages, etc.) in synovial membrane interstitium, and initiation of inflammatory reaction. Microvascular neovascularization and pannus formation the formation of new blood vessels and pannus are important pathological features of rheumatoid arthritis that further destroy joint structure. Cartilage and bone destruction, a long-term inflammatory response, can lead to destruction of cartilage and bone tissue, ultimately leading to joint deformity and dysfunction. Drug therapy mainly includes nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief and inflammation relief. The glucocorticoid has strong anti-inflammatory and immunosuppressive effects, and can rapidly relieve pain and inflammation. Antirheumatic drugs (DMARDs) including traditional DMARDs and biological agents, etc., can prevent inflammation from progressing and prevent joint tissue injury. Biological agents for the treatment of rheumatoid arthritis by inhibiting specific inflammatory mediators or pathways. Physical therapy, including thermal therapy, cold therapy, massage, physical therapy, and exercise therapy, can relieve joint pain and swelling, and improve joint function. Surgical treatment for patients with severe conditions or ineffective medication, surgical treatments such as arthroscopic surgery, joint replacement, etc. are contemplated. Rheumatoid arthritis is a progressive disease and therefore early diagnosis and early treatment are of paramount importance. Modern researches have found that saponins in Momordica Charantia have various bioactive effects, and the saponins have obvious effect of reducing blood sugar level, and the blood sugar reducing effect on animal models is slow and durable, and the saponins do not affect the fasting plasma insulin level of rats, but obviously reduce the blood sugar level and cholesterol level of postprandial rats, while the contents of myoglycogen and hepatic glycogen are obviously increased, and it is speculated that the saponins can reduce the blood sugar level by regulating the level of glucocorticoid and stimulating glycogen synthesis. In addition, the balsam pear saponin can be used for improving the immunity of model animals. Can obviously increase the number of the thymic CD8 + -T cells of the aged mice and obviously reduce the number of CD4+CD8+ double-positive T cells in thymus and spleen. Momordica saponins also exhibit some cholesterol-lowering activity. Studies show that the momordica saponins remarkably reduce the plasma cholesterol content of rats after eating and have the effect of resisting fatty liver. No report on anti-rheumatoid diseases of the momordica saponins is retrieved. Disclosure of Invention The invention provides application of a plant-derived saponin substance in preparing a medicine for treating rheumatoid arthritis. The saponins have a structure shown in a structural formula (I). The term= means selected from a double bond or a single bond,Represents a single bond or no bond, two adjacent ones of which are not simultaneously double bonds, whenWhen a single bond is formed, the carbon attached thereto is a single bond, whenWhen there is no bond, the carbon attached thereto is either a double bond or a single bond, and R1 and R3 are selected from H, OH, CH 3, and,,Any one or two or three of the glycosyl residues formed by condensation, R2, R4-R7 are independently selected from H, OH and CH 3,CHO,OCH3. Preferably, when = = adjacent to the left ring represents a double bond, the saponins compound has a structure shown in formula (II) wherein R11, R12 are selected from H, OH, CH 3, and,,Any one or two or three of the glycosyl residues formed by c